Sofia Verkhovskaia

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Background The recent Combi-v [1] and Combi-d [2,3], phase III randomized trials, showed, respectively, an OS benefit with Dabrafenib/Trametinib combination versus Vemur-afenib and an improvement in PFS and ORR with the same combination versus Dabrafenib alone, in BRAF V600E/K mutation positive metastatic or unresectable cutaneous melanoma. We report the(More)
  • 1